An attenuated vaccinia virus mutant with specific genetic lesions has been used to develop a vehicle for safer live recombinant virus vaccines. The mutant virus 48-7 has an 8-MDa deletion starting 2.2 MDa from the left end of the viral genome and point mutations in the gene encoding the 14-kDa fusion protein that determines the plaque-size phenotype of the virus. Using the highly sensitive reporter gene luciferase, we have shown that this mutant can generate recombinant viruses that infect cultured cells and animals with normal vaccinia virus tropism. Insertion of the envelope and gag genes of human immunodeficiency virus type 1 into the attenuated vaccinia mutant resulted in their efficient expression and precursor processing in infected cultured cells. Infection of mice with human immunodeficiency virus-vaccinia recombinant viruses elicited human immunodeficiency virusspecific antibodies. Using mice pretreated with cyclophosphamide as a model for immunosuppression, the reduced virulence of the mutant recombinant virus was clearly evident. These findings demonstrate that the highly attenuated vaccinia virus mutant 48-7 can be used to generate effective and safer vaccines.
Genetically engineered recombinants of vaccinia virus are now used as eukaryotic expression vectors and, because they are potent immunogens, have a potential as vaccines against a broad spectrum of infectious pathogens of animals and human significance (1) (2) (3) . However, in humans, accidental vaccination with live vaccinia virus of an immunocompromised host can lead to serious and lethal complications, such as systemic vaccinia infection with encephalitis (4, 5) . This point was confirmed by the vaccination of a soldier who unknowingly was seropositive for human immunodeficiency virus (HIV) (6) . To diminish the chances of producing such complications, an expert panel from the World Health Organization has recommended the development of attenuated strains of vaccinia virus that carry identifiable genetic markers upon which to base the construction of future recombinant vaccines (7) . Attenuated variants of vaccinia virus have been obtained by several methods, including (i) inactivation of the viral thymidine kinase gene (8) , (ii) generation of deletions at the left end of the viral genome (9, 10) , (iii) mutation of the gene encoding a 14-kDa fusion protein that influences viral plaque size (11) , (iv) alterations in size of virion core proteins (12, 13) , and (v) insertion of the interleukin 2 gene that greatly decreases virus virulence in athymic nude mice (14, 15) .
In this report we describe the effectiveness of recombinant vaccines based on an attenuated vaccinia virus mutant that has specific genetic lesions. Using (17) . Luciferase activity was measured with a spectrophotometer and results were quantitated as described (18) . For the construction of HIVvaccinia recombinants, an Xba I-Xho I DNA fragment containing the coding region of HIV env was created by standard recombinant DNA techniques from a full-length HIV type 1 (HIV-1) DNA genome (19) . This fragment extends to the Ssp I site 66 bp upstream from the start site of translation of the env gene and 100 bp downstream from the termination codon. The env DNA fragment was blunt-ended by treatment with the Klenow fragment of DNA polymerase I and cloned into the Sma I site of the vaccinia virus insertion vector pSC11. As a result of this cloning strategy, we isolated a plasmid containing HIV env coding sequence under the control of the 7.5-kDa vaccinia virus promoter. A similar strategy was used to construct vaccinia virus insertion vectors containing the intact HIV gag gene. A BssHII-EcoRI DNA fragment containing the coding region of gag was isolated from the full-length HIV-1 DNA. This fragment contains 79 bp upstream from the start site of translation of the gag gene and, from the termination site, it contains 2358 bp of the pol gene. The luciferase, env, and gag genes were inserted in the correct orientation relative to the vaccinia 7.5-kDa promoter and into the thymidine kinase region of wild-type and mutant viruses by DNA homologous recombination. P -Galactosidase-producing plaques (17) tTo whom reprint requests should be addressed.
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Proc. Natl. Acad. Sci. USA 86 (1989) at 40,u g/ml. At various times after infection, cells were collected and cell extracts prepared in luciferase buffer (100 mM potassium phosphate/1 mM dithiothreitol) were tested for luciferase activity in the presence of luciferin and ATP (18) . (B) Expression of luciferase in organs of infected mice. BALB/c female mice, 6 weeks old (Charles River Breeding Laboratories), were inoculated i.p. with 5 x 105 pfu of recombinant vaccinia viruses and 3 days later tissues were washed in isotonic phosphate-buffered saline (PBS), weighed, homogenized in luciferase buffer containing 1 mM phenylmethylsulfonyl fluoride and leupeptin at 10ttg/ml (5t 1/mg of tissue), and supernatants were assayed for luciferase activity (18 1A , the levels of luciferase activity were equivalent in monkey cells infected with the luciferase-wild-type recombinant or with the luciferase-mutant 48-7 recombinant. In infected mice luciferase activity was observed in spleen and liver, the known target organs for wild-type vaccinia virus multiplication (20) . The levels of luciferase activity found in spleens of mice inoculated with the luciferase-mutant recombinant virus were =30% lower than in mice inoculated with the wild-type recombinant virus. Thus, the mutant recombinant virus efficiently expresses a foreign gene and shows the same tissue tropism as the wild-type virus.
Expression of HIV Envelope and gag Genes by Attenuated Vaccinia Recombinants. To assess that the attenuated vaccinia virus mutant has a vaccine potential, we constructed recombinant viruses containing either the HIV-1 env or the gag gene and studied their expression and immunogenicity. Because mature retroviral gag and envelope proteins are derived from precursor molecules by processing (21-23), we first examined processing of env and gag by immunoprecipitation analysis. The results are shown in Fig. 2 A and Genetics: Rodriguez et al.
lysates of Hela S3 cells infected with wild-type HIV-vaccinia env virus, monoclonal antibodies against gp120 immunoprecipitates both gp120 and its precursor gpl60 (Fig. 2A, lane 6) . These polypeptides were also detected in lysates of cells infected with the mutant recombinant virus (lane 8). However, these polypeptides were not detected in lysates of uninfected cells (lane 2) or in cells infected with nonrecombinant virus (lane 4). In lysates of cells infected with HIVvaccinia gag recombinants (either wild-type or mutant virus), a monoclonal antibody against p24 has specific reactivity with polypeptides p56, p42, p32, and p24 (Fig. 2B, lanes 6 and  8) . Next we establish a precursor-product relationship for env by pulse-chase experiments (Fig. 2C) . The polypeptide that was most labeled during the pulse period was gpl60, which was chased into gpl20. The chased gpl20 was released extracellularly and was recovered in the cell culture supernatant (lane 7). Two other immunoreactive bands of 70 and 50 kDa (lane 7) were also found and appear to result from a single nick in gp120 (unpublished results). To determine if mutant HIV-vaccinia recombinants elicit specific antibodies against env and gag proteins, mice were vaccinated with the recombinants and serum was tested by Western blot and ELISA. We found that mice vaccinated with mutant HIVvaccinia env virus have weak antibody response to gpl60.
However, induction of antibodies to gp160 was markedly increased if vaccinated mice were given a booster injection with purified gpl60 (Fig. 3A, lane 5) . Mice only vaccinated with mutant HIV-vaccinia gag virus had a strong immune response to gag (Fig. 3B, lane 6 ). Immune reactivity to env A 100 j 75 50- 25- and gag proteins in serum samples was also confirmed by ELISA with HIV-infected cell extracts (Pasteur Institute). Reduced Virulence of Attenuated HIV-Vaccinia Recombinants in Immunosuppressed Animals. Since it is known that inoculation of immunocompromised individuals with vaccinia virus may lead to generalized vaccinia and encephalitis (4, 5) [and indeed, this has been documented in a vaccinated male seropositive for HIV (6)], it was important to assess the degree of virulence of attenuated HIV-vaccinia recombinants in an immunosuppressed host. Thus, BALB/c mice were first treated with the immunosuppressor drug cyclophosphamide (24) and subsequently infected, and their survival was evaluated daily (Fig. 4) . As expected, in normal mice the mortality produced by the vaccinia mutant was about 100 times lower than that induced by wild-type virus (Fig. 4A) . Significantly, the differences in mortality between the two viruses were greater with immunosuppressed mice (Fig. 4B) . This was also the case with mutant recombinant virus. As shown in Fig. 4 C and D (25, 26) . However, the processing of HIV-1 gag precursors that we have observed with HIVvaccinia recombinant has not been observed, and only the unprocessed form of gag p56 has been reported with a wild-type HIV-vaccinia gag recombinant (27) . Processing of gag precursors by our vaccinia recombinants is likely to be due to the function of the protease encoded by the 5' end of the pol gene contained in the BssHII-EcoRI fragment used to introduce the gag sequence as a result of ribosomal "frameshifting" (28) . Of significance in our study is that mice vaccinated with attenuated HIV-vaccinia recombinants develop antibodies to env and gag proteins. The immune response to the gag protein was stronger than to the env protein. However, if after vaccination mice were given a booster injection i.v. with purified gpl60, we then observed good antibody response to the env protein (Fig. 3A) .
In this study we have established an immunosuppressed mouse model system to evaluate virulence of vaccinia virus recombinants. In this animal-virus system, we observed clear differences in mortality between recombinant viruses that correlated with the viral genetic markers (Fig. 4) . In fact, inactivation of wild-type vaccinia thymidine kinase locus that is known to reduce virulence in normal mice (8) , has little effect in decreasing virulence in immunosuppressed animals. However, a vaccinia recombinant with a left-end deletion and alterations in the 14-kDa fusion protein encoding gene has about 100 times less virulence in immunosuppressed animals than a wild-type recombinant with a thymidine kinasenegative phenotype. Thus, a potential advantage in generating highly attenuated vaccinia virus recombinants with deletions and point mutations is that these types of recombinants will greatly decrease the risk of virus dissemination after vaccination, particularly in an immunocompromised host.
Considering the characteristics of the highly attenuated vaccinia recombinants that we have generated, these recombinants and derivatives might be useful as immunogens in studies of recognition specificity of immune T cells and in the design of safer vaccines against pathogens of veterinary and human importance.
